A Cohort Study on Anti-microbial Stewardship in PICU
- Sponsor
- Children's Hospital of Fudan University
- Study ID
- NCT05862688
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Infections
Eligibility Criteria
- Sex
- ALL
- Age
- 1 Month - 18 Years
- Healthy Volunteers
- Not accepted
Interventions
- antimicrobial therapy — OTHERantimicrobial therapy
Study Details
Appropriate antimicrobial therapy is essential to ensuring positive patient outcomes. Inappropriate or suboptimal utilization of antibiotics can lead to increased length of stay, multidrug-resistant infections, and mortality. Critically ill intensive care patients are at risk of antibiotic failure and secondary infections associated with incorrect antibiotic use. Initiating effective therapy for infections based upon patients' risk factors, collection of appropriate cultures, daily evaluation of clinical status, and laboratory data, including antibiotic time outs, and shortened duration of therapy are ways to improve patients outcomes. Antimicrobial stewardship teams can assist ICU providers in managing and implementing these tactics. ICUs would benefit from employing empiric guidelines for antibiotic use, collecting appropriate specimens and implementing molecular diagnostics, optimizing the dosing of antibiotics, and reducing the duration of total therapy.
Key Dates
- First listed
- May 17, 2023
- Start date
- Jul 1, 2026
- Status verified
- Feb 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 1,000 participants (estimated)
Arms
- Arm: Infectionpatients with infection
- Arm: non-infectionpatients without infection
Primary Outcome Measure
survival rate [ Time Frame: 21 days after ICU admission ]
Central Contacts
- Jing Liu, Doctor15800523953
Related Studies
- Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- A Phase I Study of Mozobil in the Treatment of Patients With WHIMSPHASE1/PHASE2 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient OutcomesEnrolling By Invitation · Brigham and Women's Hospital · Boston, Massachusetts
- CIED Infection Quality Initiative Demonstration ProjectRecruiting · Duke University · Chicago, Illinois